In another EAE study, oral treatment with obeticholic acid (6α-ethyl-chenodeoxycholic acid, 6-ECDCA), a synthetic FXR agonist, identified FXR as a negative regulator of neuroinflammation, suggesting FXR agonists might serve as a potential therapy compound for MS [43]. This evidence concerns the gene NR1H4 and myeloid sarcoma.